Race Oncology Limited
50 Kings Park Road
Level 2
West Perth
Western
6005
Tel: 1300-288-664 or 61-2-9698-5414
Website: http://www.raceoncology.com/
Email: info@raceoncology.com
About Race Oncology Limited
Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage drug assets, principally in the cancer field. Our first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies, before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology is rediscovering Bisantrene. We own recent patent filings on Bisantrene and have secured Orphan Drug Designation in the US. Now our goal is to complete final development of Bisantrene and bring this valuable cancer drug to market.YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Peter Molloy
CSO: Dr. John Rothman
Senior VP, Business Development: Gordon Beck
Chairman: Dr. William Garner
Director: Dr. Brendan de Kauwe
Director: Chris Ntoumenopoulos
5 articles about Race Oncology Limited
-
Race Strategic Update August 2023
8/8/2023
Race Oncology Limited is pleased to provide a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene's commercial partnering and collaboration potential.
-
Race executes agreement with Ardena for GMP manufacturing of RC220
7/12/2023
Race Oncology executes agreement with leading global contract development and manufacturing organisation, Ardena as additional partner for GMP manufacturing of flagship RC220 bistanrene formulation.
-
Race executes global license agreement with City of Hope to access FTO IP
7/10/2023
Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States.
-
AML biotech Race Oncology (RAC) strengthens board with prominent biotech investor Dr Daniel Tillet
9/17/2019
Race Oncology Limited is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has joined the Board of Directors of Race Oncology Ltd.
-
Prominent biotech investor leads investment in Race
8/20/2019
Race Oncology Limited announced the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett.